Analysts Issue Forecasts for Passage Bio, Inc.’s Q1 2023 Earnings (NASDAQ:PASG)

Passage Bio, Inc. (NASDAQ:PASG – Get Rating) – Stock analysts at Wedbush decreased their Q1 2023 earnings estimates for shares of Passage Bio in a research report issued to clients and investors on Monday, March 6th. Wedbush analyst L. Chico now forecasts that the company will earn ($0.50) per share for the quarter, down from their previous estimate of ($0.44). Wedbush has a “Outperform” rating on the stock. The consensus estimate for Passage Bio’s current full-year earnings is ($1.92) per share. Wedbush also issued estimates for Passage Bio’s Q2 2023 earnings at ($0.51) EPS, Q3 2023 earnings at ($0.52) EPS, Q4 2023 earnings at ($0.42) EPS, FY2023 earnings at ($1.92) EPS, FY2024 earnings at ($1.57) EPS, FY2025 earnings at ($1.47) EPS, FY2026 earnings at ($1.37) EPS and FY2027 earnings at ($0.97) EPS.

Passage Bio (NASDAQ:PASG – Get Rating) last announced its quarterly earnings data on Monday, March 6th. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). During the same period in the previous year, the firm posted ($0.93) earnings per share.

Several other equities research analysts have also recently issued reports on the stock. Citigroup cut their price objective on shares of Passage Bio from $7.00 to $5.00 and set a “buy” rating for the company in a research report on Friday, November 11th. BTIG Research reduced their price target on shares of Passage Bio to $9.00 in a research report on Wednesday, November 16th. Chardan Capital decreased their price objective on Passage Bio from $18.00 to $11.00 and set a “buy” rating on the stock in a report on Thursday, December 15th. Finally, Guggenheim cut their target price on Passage Bio from $13.00 to $11.00 and set a “buy” rating for the company in a research note on Friday, November 11th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Passage Bio currently has a consensus rating of “Buy” and an average price target of $8.80.

Passage Bio Stock Down 4.6 %

NASDAQ PASG opened at $1.25 on Thursday. The business’s fifty day simple moving average is $1.45 and its 200-day simple moving average is $1.43. The firm has a market cap of $68.28 million, a PE ratio of -0.50 and a beta of 1.03. Passage Bio has a 52 week low of $1.04 and a 52 week high of $3.56.

Institutional Trading of Passage Bio

Several institutional investors have recently added to or reduced their stakes in PASG. Annandale Capital LLC lifted its stake in Passage Bio by 35.8% during the fourth quarter. Annandale Capital LLC now owns 54,338 shares of the company’s stock worth $75,000 after purchasing an additional 14,338 shares in the last quarter. BML Capital Management LLC acquired a new position in Passage Bio during the 4th quarter worth about $466,000. GSA Capital Partners LLP lifted its stake in Passage Bio by 25.4% during the 4th quarter. GSA Capital Partners LLP now owns 106,836 shares of the company’s stock worth $147,000 after acquiring an additional 21,640 shares in the last quarter. New York Life Investment Management LLC boosted its holdings in Passage Bio by 12.7% during the 4th quarter. New York Life Investment Management LLC now owns 182,978 shares of the company’s stock valued at $253,000 after acquiring an additional 20,617 shares during the period. Finally, Bailard Inc. acquired a new position in Passage Bio in the 4th quarter valued at about $217,000. Institutional investors and hedge funds own 76.99% of the company’s stock.

About Passage Bio

(Get Rating)

Passage Bio, Inc, a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease.